RNAi / siRNA Deal Benchmarks in Oncology
Market Analysis
RNAi / siRNA therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 rnai / sirna asset in oncology is $297M, with total deal values reaching $1.9B. Development milestones average $397M, while regulatory milestones contribute $634M.
The oncology rnai / sirna landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for rnai / sirna oncology deals range from 12.3% to 20.1% at the base tier, with tiered escalation reaching 16.3%-24.1% on blockbuster sales. Commercial milestones averaging $555M further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a rnai / sirna oncology licensing deal?
What is the total deal value for rnai / sirna oncology transactions?
What royalty rates are standard for rnai / sirna deals in oncology?
How are milestones structured in rnai / sirna oncology deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.